<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05042973</url>
  </required_header>
  <id_info>
    <org_study_id>S-20210028-2</org_study_id>
    <nct_id>NCT05042973</nct_id>
  </id_info>
  <brief_title>The Metabolic Effects of Empagliflozin in Patients With High Risk of Heart Failure</brief_title>
  <official_title>Empagliflozin to Elderly and Obese Patients With Cardiovascular Disease (EMPIRE II Metabolic): A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jacob Moller</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Danish Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Herlev and Gentofte Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Bispebjerg and Frederiksberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hillerod Hospital, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this trial is to assess the effect of Empagliflozin on lipid and glucose&#xD;
      metabolism as well as volume homeostasis and renal function in elderly and obese patients&#xD;
      with increased risk of developing heart failure. No history of established heart failure or&#xD;
      diabetes is allowed.&#xD;
&#xD;
      The primary hypotheses are that 6 months treatment with Empagliflozin 10 mg a day will: 1)&#xD;
      decrease epicardial adipose tissue volume, and 2) reduce estimated extracellular volume&#xD;
      compared with placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The EMPIRE II Metabolic is a part of the EMPIRE II Trial Program, which also comprises the&#xD;
      EMPIRE II Cardiac.&#xD;
&#xD;
      The EMPIRE II Metabolic is designed to enroll at least 120 patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2, 2021</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Assignment</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Epicardial adipose tissue (EAT)</measure>
    <time_frame>180 days</time_frame>
    <description>Between-group difference in the change of EAT volume assessed by cardiac MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Estimated extracellular volume (eECV)</measure>
    <time_frame>180 days</time_frame>
    <description>Between-group difference in the change of eECV assessed by 99mTc-DTPA clearance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body composition</measure>
    <time_frame>180 days</time_frame>
    <description>Between-group difference in the change in body composition assessed by DXA scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma volume</measure>
    <time_frame>180 days</time_frame>
    <description>Between-group difference in the change of estimated plasma volume assessed by hematocrit and hemoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose tolerance</measure>
    <time_frame>180 days</time_frame>
    <description>Between-group difference in the change of glucose metabolism assessed by oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney function (measured)</measure>
    <time_frame>180 days</time_frame>
    <description>Between-group difference in the change of glomerular filtration rate assessed by 99mTc-DTPA clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney function (estimated)</measure>
    <time_frame>180 days</time_frame>
    <description>Between-group difference in the change of estimated glomerular filtration based on the CKD-EPI estimation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uric acid</measure>
    <time_frame>180 days</time_frame>
    <description>Between-group difference in the change of uric acid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine albumin/creatinine ratio</measure>
    <time_frame>180 days</time_frame>
    <description>Between-group difference in the change of urine albumin/creatinine ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Right ventricle</measure>
    <time_frame>180 days</time_frame>
    <description>Between-group difference in the change of right ventricular systolic and diastolic dimensions assessed by cardiac MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pericardial fat mass</measure>
    <time_frame>180 days</time_frame>
    <description>Between-group difference in the change of pericardial fat mass assessed by cardiac MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ketone bodies</measure>
    <time_frame>180 days</time_frame>
    <description>Between-group difference in the change of ketone supply to the heart assessed by blood ketones</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythropoietin</measure>
    <time_frame>180 days</time_frame>
    <description>Between-group difference in the change of eryhtropoietin</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory outcome: fat tissue gene expression</measure>
    <time_frame>180 days</time_frame>
    <description>Between-group difference in fat tissue gene expression assessed by Western Blot</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory outcome: oxidative stress and inflammation.</measure>
    <time_frame>180 days</time_frame>
    <description>Between-group difference in biomarkers of oxidative stress and inflammation.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Obesity</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Active drug (Empagliflozin)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Empagliflozin 10 mg, 1 capsule per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inactive drug (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, 1 capsule per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin 10 MG</intervention_name>
    <description>Patients are randomized 1:1 to receive either Empagliflozin or matching placebo for 180 days</description>
    <arm_group_label>Active drug (Empagliflozin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matches the active drug in appearance, odor and labelling.</description>
    <arm_group_label>Inactive drug (placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body mass index &gt;28kg/m2&#xD;
&#xD;
          -  Age 60-84 years&#xD;
&#xD;
          -  Established risk factor for developing heart failure, defined as at least one of the&#xD;
             following:&#xD;
&#xD;
          -  hypertension&#xD;
&#xD;
          -  ischemic heart disease&#xD;
&#xD;
          -  stroke/transient cerebral ischemia&#xD;
&#xD;
          -  chronic kidney disease (eGFR 30-45ml/min/1.73m2)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diabetes mellitus type 1 or 2 (no medical history, no antidiabetic treatment)&#xD;
&#xD;
          -  Heart failure with reduced ejection fraction (LVEF &lt;40%)&#xD;
&#xD;
          -  Inability to perform exercise test&#xD;
&#xD;
          -  Dementia&#xD;
&#xD;
          -  Severe non-compliance&#xD;
&#xD;
          -  Substance abuse&#xD;
&#xD;
          -  Severe chronic obstructive pulmonary disease (FEV1&lt;50% expected value)&#xD;
&#xD;
          -  Permanent atrial fibrillation&#xD;
&#xD;
          -  GFR &lt;30 ml/min/1,73m2&#xD;
&#xD;
          -  Severe peripheral artery disease&#xD;
&#xD;
          -  Cancer treatment within one year beside prostate cancer and basal cell carcinoma&#xD;
&#xD;
          -  Severe aortic or mitral valve disease&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Acute hospital admission within 30 days&#xD;
&#xD;
          -  Participation in other pharmacological study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>84 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Morten Schou, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herlev-Gentofte Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jacob Eifer Møller, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Odense University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Camilla Fuchs Andersen, MD</last_name>
    <phone>+45 28144737</phone>
    <email>camilla.fuchs.andersen@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julie Hempel Larsen, MD</last_name>
    <phone>+45 28935466</phone>
    <email>julie.hempel.larsen@rsyd.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Camilla F Andersen, MD</last_name>
      <phone>+45 28144737</phone>
      <email>camilla.fuchs.andersen@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Professor Morten Schou, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Camilla F Andersen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie H Larsen, MD</last_name>
      <phone>+45 28935466</phone>
      <email>Julie.Hempel.Larsen@rsyd.dk</email>
    </contact>
    <investigator>
      <last_name>Professor Jacob E Møller, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julie H Larsen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 3, 2021</study_first_submitted>
  <study_first_submitted_qc>September 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2021</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Jacob Moller</investigator_full_name>
    <investigator_title>Professor, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Renal function</keyword>
  <keyword>Glucose intolerance</keyword>
  <keyword>Lipid metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

